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Background: Periprocedural non-Q-wave myocardial infarction (PMI) is a frequent and prognostically important complication of percutaneous 
coronary intervention (PCI). Recently, statins pretreatment has been recommended for the prevention of PMI, but its effectiveness remains 
controversial. We therefore performed a meta-analysis based on all currently available randomized controlled trials (RCT) to evaluate the beneficial 
effects of statins given before PCI on preventing PMI.
Methods: The published literature was scanned by formal searches of electronic databases (PubMed, EMBASE and the Cochrane Central Register 
of Controlled Trials) and conference proceedings up through August 2009. RCTs were eligible for inclusion if they compared preprocedural statins 
versus placebo treatment in patients not taking statins previously but scheduled for PCI and had the data of PMI reported by the trial investigators.
Results: A total of 6 RCTs were finally included in this meta-analysis, involving 2,088 patients (1051 in the statins pretreatment group and 1037 
in the control group). During the periprocedural period, 81 of 1051 patients (7.7%) in the statins pretreatment group developed PMI, significantly 
less than 147 of 1037 (14.2%) patients assigned to the control group (OR 0.51, 95% CI 0.38 to 0.67; P < 0.001; P = 0.55 for heterogeneity). During 
1 month follow-up, only 4 deaths (1 in the statins pretreatment group and 3 in the control), 7 non-periproceduarl Q-wave MIs (2 in the statins 
pretreatment group and 5 in the control), and 4 revascularizations (all in the control) occurred in all 2088 enrolled patients. The composite of 
death, MI or TVR at 1 month, essentially driven by PMI, was reported in 8.0% in the statins pretreatment group and 15.3% in the control group (OR 
0.48, 95% CI 0.36 to 0.64; P < 0.001; P = 0.40 for heterogeneity).
Conclusions: This meta-analysis confirms the effectiveness of statins pretreatment on reducing the rate of PMI following PCI. Further studies are 
needed to identify the optimal statin type, dose and time of onset before percutaneous revascularization.
